AR and Familial prostate cancer: ARD-69 showed effective AR degradation activity in LNCaP (DC50 = 0.86 nM), VCap (DC50 = 0.76 nM), and 22Rv1 prostate cancer cell lines and in a VCaP xenograft mouse model [43].